A5101487802- Trypanosoma species research and implications
- Research on Leishmaniasis Studies
- Parasites and Host Interactions
- Travel-related health issues
- Parasite Biology and Host Interactions
- Malaria Research and Control
- Lysosomal Storage Disorders Research
- Viral Infections and Vectors
- Mosquito-borne diseases and control
- Dermatological diseases and infestations
- Poxvirus research and outbreaks
- Mollusks and Parasites Studies
- Helminth infection and control
- Parasitic infections in humans and animals
- Cardiomyopathy and Myosin Studies
- Child Nutrition and Feeding Issues
- Mycobacterium research and diagnosis
- European Socioeconomic and Political Studies
- Toxoplasma gondii Research Studies
- Urticaria and Related Conditions
- Congenital Anomalies and Fetal Surgery
- Defense, Military, and Policy Studies
- Amoebic Infections and Treatments
- Eosinophilic Disorders and Syndromes
- Parasitic Infections and Diagnostics
Swiss Tropical and Public Health Institute
2015-2024
University of Basel
2013-2024
Kinshasa General Hospital
2020-2022
James Cook University
2021
Université Evangélique en Afrique
2019
Barcelona Institute for Global Health
2018
Universitat de Barcelona
2018
University Hospital of Basel
2015
University of Zurich
2010
University of Applied Sciences Mainz
2009
Characterizing the Zika virus antibody response Given public health emergency that poses, scientists are seeking to understand Zika-specific immune response. Stettler et al. analyzed 119 monoclonal antibodies isolated from four donors were infected with during present epidemic, including two individuals had previously been dengue virus, another member of flavivirus family. Neutralizing primarily recognized envelope protein domain III (EDIII) or quaternary epitopes on intact and an...
International travel contributes to the worldwide spread of multidrug resistant Gram-negative bacteria. Rates travel-related faecal colonization with extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae vary for different destinations. Especially travellers returning from Indian subcontinent show high rates. So far, nothing is known about region-specific risk factors becoming colonized. An observational prospective multicentre cohort study investigated South Asia. Before and...
This review addresses the question of whether risk developing mucosal leishmaniasis (ML) warrants systemic treatment in all patients with New World cutaneous (CL) or local might be an acceptable alternative. The CL ML after initial infection has been main argument for treatment. However, this statement needs re-evaluation and consideration available data. putative benefit preventing should outweigh toxicity antileishmanial therapy. To assess need following factors were reviewed: incidence...
Encephalopathies are the most feared complications of sleeping sickness treatment with melarsoprol. To investigate existence risk factors, incidence encephalopathic syndromes and relationship between development different types encephalopathies clinical outcome was studied in a trial 588 patients under The 38 encephalopathy cases were classified into three according to leading picture: coma type, convulsion type psychotic reactions. Nine attributed defined as transient event short duration...
Background Surveillance of human leishmaniasis in Europe is mostly limited to country-specific information from autochthonous infections the southern part. As at end 2021, no integrated analysis has been performed for cases seen across centres different European countries. Aim To provide a broad perspective on and imported endemic non-endemic countries Europe. Methods We retrospectively collected records cutaneous, mucosal visceral diagnosed 15 between 2014 2019. Centres were located 11...
Background A wide spectrum of disease severity has been described for Human African Trypanosomiasis (HAT) due to Trypanosoma brucei rhodesiense (T.b. rhodesiense), ranging from chronic patterns in southern countries East Africa an increase virulence towards the north. However, only limited data on clinical presentation T.b. HAT is available. From 2006-2009 we conducted first trial program (Impamel III) endemic areas Tanzania and Uganda accordance with international standards (ICH-GCP). The...
Complex cutaneous and muco-cutaneous leishmaniasis (CL MCL) often requires systemic therapy. Liposomal amphotericin B (L-AmB) has a strong potential for solid clinical benefit in this indication. We conducted retrospective analysis of data from French centralized referral treatment program the "LeishMan" European consortium database. All patients with parasitologically proven CL or MCL who received at least one dose L-AmB were included. Positive outcome was based on ulcer closure as per...